Vor Biopharma Inc (VOR) - Net Assets
Based on the latest financial reports, Vor Biopharma Inc (VOR) has net assets worth $-200.20 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($481.05 Million) and total liabilities ($681.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VOR PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-200.20 Million |
| % of Total Assets | -41.62% |
| Annual Growth Rate | N/A |
| 5-Year Change | -175.98% |
| 10-Year Change | N/A |
| Growth Volatility | 267.57 |
Vor Biopharma Inc - Net Assets Trend (2018–2025)
This chart illustrates how Vor Biopharma Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see VOR market cap overview.
Annual Net Assets for Vor Biopharma Inc (2018–2025)
The table below shows the annual net assets of Vor Biopharma Inc from 2018 to 2025. Also explore Vor Biopharma Inc (VOR) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-164.31 Million | -269.98% |
| 2024-12-31 | $96.66 Million | -35.87% |
| 2023-12-31 | $150.72 Million | -39.86% |
| 2022-12-31 | $250.61 Million | +15.88% |
| 2021-12-31 | $216.26 Million | +348.02% |
| 2020-12-31 | $48.27 Million | +531.82% |
| 2019-12-31 | $7.64 Million | +212.90% |
| 2018-12-31 | $-6.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vor Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 114592700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.00K | % |
| Other Comprehensive Income | $41.00K | % |
| Other Components | $988.60 Million | % |
| Total Equity | $-164.31 Million | 100.00% |
Vor Biopharma Inc Competitors by Market Cap
The table below lists competitors of Vor Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Yuchai International Limited
NYSE:CYD
|
$1.30 Billion |
|
Aptus Value Housing Finance India Limited
NSE:APTUS
|
$1.30 Billion |
|
Cpi Fim SA
WAR:OPG
|
$1.30 Billion |
|
Alphamin Res
V:AFM
|
$1.30 Billion |
|
Suzhou Victory Precision Manufacture Co Ltd
SHE:002426
|
$1.29 Billion |
|
Stanley Fertilizer Co Ltd
SHE:002588
|
$1.29 Billion |
|
Taiwan FamilyMart Co Ltd
TWO:5903
|
$1.29 Billion |
|
Max Stock Ltd
TA:MAXO
|
$1.29 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vor Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 96,664,000 to -164,312,000, a change of -260,976,000 (-270.0%).
- Net loss of 695,981,000 reduced equity.
- New share issuances of 328,206,000 increased equity.
- Other comprehensive income increased equity by 19,000.
- Other factors increased equity by 106,780,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-695.98 Million | -423.57% |
| Share Issuances | $328.21 Million | +199.75% |
| Other Comprehensive Income | $19.00K | +0.01% |
| Other Changes | $106.78 Million | +64.99% |
| Total Change | $- | -269.98% |
Book Value vs Market Value Analysis
This analysis compares Vor Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-23.91 | $21.89 | x |
| 2019-12-31 | $4.12 | $21.89 | x |
| 2020-12-31 | $26.00 | $21.89 | x |
| 2021-12-31 | $116.35 | $21.89 | x |
| 2022-12-31 | $126.72 | $21.89 | x |
| 2023-12-31 | $44.86 | $21.89 | x |
| 2024-12-31 | $28.14 | $21.89 | x |
| 2025-12-31 | $-16.64 | $21.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vor Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-62.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.48 Million |
| 2019 | -141.87% | 0.00% | 0.00x | 1.29x | $-11.60 Million |
| 2020 | -89.78% | 0.00% | 0.00x | 1.57x | $-48.16 Million |
| 2021 | -31.86% | 0.00% | 0.00x | 1.12x | $-90.53 Million |
| 2022 | -36.75% | 0.00% | 0.00x | 1.19x | $-117.15 Million |
| 2023 | -78.20% | 0.00% | 0.00x | 1.39x | $-132.94 Million |
| 2024 | -120.95% | 0.00% | 0.00x | 1.48x | $-126.58 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-679.55 Million |
Industry Comparison
This section compares Vor Biopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vor Biopharma Inc (VOR) | $-200.20 Million | 0.00% | N/A | $1.30 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more